PROK Stock Chart & Stats
$27.50
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$26.90 - $66.63
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.34K
Market Cap
$7.92B
Enterprise Value$1.32K
Total Cash (Recent Filing)$224.94M
Total Debt (Recent Filing)$3.78M
Price to Earnings (P/E)―
Beta-3.93
Next Earnings
Aug 06, 2026EPS Estimate
-2.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding205,199,700
10 Day Avg. Volume9,778
30 Day Avg. Volume5,345
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Alignment (eGFR Surrogate)FDA recognition of eGFR slope as a surrogate endpoint materially reduces regulatory execution risk for rilparencel. This alignment makes an accelerated pathway feasible, shortening timelines for approval conditional on trial success and improving the long-term commercial viability of a novel CKD cell therapy.
Near-term Cash RunwayHaving roughly $225M in cash expected to fund operations into mid-2027 provides multi-quarter funding stability to complete pivotal enrollment and topline readout. This liquidity supports continuity of critical clinical and manufacturing activities over the 2-6 month horizon tied to the Phase 3 program.
Low Financial LeverageVery low reported debt minimizes near-term solvency pressures and interest burden, giving ProKidney flexibility to prioritize R&D spending. For a pre-revenue biotech, limited leverage reduces bankruptcy risk and preserves optionality for equity or partnership financing over the development cycle.
Bears Say
High Cash BurnSustained and large negative operating and free cash flow reflect heavy R&D and manufacturing spend required for pivotal trials. Persistent burn pressures the balance sheet and creates a structural need for additional financing before commercialization, increasing execution and financing risk over the medium term.
Minimal, Declining RevenueProKidney remains pre-commercial with negligible and falling revenue, so it cannot internally fund development. The company's long-term sustainability depends on successful clinical outcomes or external capital/partnerships, leaving operational resilience vulnerable until product approval and commercialization.
Balance-sheet Volatility And Past Negative EquityHistorical negative equity and a large decline in reported assets indicate prior capital raises, remeasurements, or impairments, reducing predictability of future financials. Such structural volatility signals potential dilution risk and uncertainty around asset values and capitalization as the company funds development.
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $26.90 and its highest was $66.63 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $7.92B.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is Aug 06, 2026 which is in 11 days.
How were Prokidney Corp.’s earnings last quarter?
Prokidney Corp. released its earnings results on May 15, 2026. The company reported -$2.451 earnings per share for the quarter, missing the consensus estimate of -$2.416 by -$0.035.
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate is -2.45.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 205,199,700 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Prokidney Corp. reported an EPS of -$2.451 in its last earnings report, missing expectations of -$2.416. Following the earnings report the stock price went down -1.894%.
Which hedge fund is a major shareholder of Prokidney Corp.?
Currently, no hedge funds are holding shares in MX:PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.90%
Trailing 12-Months
Company Description
Prokidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.